Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse
We identified 103 consecutive patients who, 5 years after allogeneic transplantation for chronic myeloid leukaemia (CML), were in molecular remission (MR). The 103 patients were divided into three groups on the basis of reverse transcription–polymerase chain reaction (RT–PCR) studies for BCR-ABL transcripts in the first 5 years post transplant: Group A comprised 63 patients who had been continuously PCR negative; Group B comprised 20 patients with one or more positive PCR result but only at a low level; and Group C comprised 20 patients who had fulfilled the criteria for molecular relapse, been treated with donor lymphocyte infusions (DLI) and had thereafter regained complete MR within the 5-year post-transplant period. The median follow-up for all 103 patients was 8·4 years from transplant (range 5–17·6 years). In group A only one patient relapsed at 9·2 years. In group B eight patients (40%) relapsed: six at molecular, one at cytogenetic and one haematological levels. The actuarial probabilities of survival at 10 years for patients in Groups A, B and C were 97·4%, 92·9% and 100% respectively; the probabilities of relapse were 3%, 54% and 0% respectively. We conclude that molecular studies during the first 5 years post transplant can help to predict long-term leukaemia-free survival and, possibly, cure of CML.
569 - 574
Mughal, T. I.
dd3de280-7761-4b5b-a85b-3447a1397c67
Yong, A.
8d263672-483d-44c8-84f8-74b6e7c7b1ff
Szydlo, R. M.
040901f0-592d-4a80-9144-8e44680e56d2
Dazzi, F.
7ef9de2e-64dc-4712-8a96-f37b551751ed
Olavarria, E.
7009b036-d0e0-46ba-960e-564fe5f5e7d7
Van Rhee, F.
0928f5f5-f11e-4e3f-a3e4-8e27910398eb
Kaeda, J.
97eba745-9c30-4333-9235-00c915b12cf6
Cross, N. C.
f87650da-b908-4a34-b31b-d62c5f186fe4
Craddock, C.
10587977-6515-440b-92fb-0b5dd2190bfe
Kanfer, E.
d2fe82c8-6e91-4587-95f7-2a174ad95ce5
Apperley, J.
622c945c-74c1-4773-a80f-2bdafe8dfe14
Goldman, J. M.
2c27a1b3-c445-4593-a6b5-2e6e749fa1cb
2001
Mughal, T. I.
dd3de280-7761-4b5b-a85b-3447a1397c67
Yong, A.
8d263672-483d-44c8-84f8-74b6e7c7b1ff
Szydlo, R. M.
040901f0-592d-4a80-9144-8e44680e56d2
Dazzi, F.
7ef9de2e-64dc-4712-8a96-f37b551751ed
Olavarria, E.
7009b036-d0e0-46ba-960e-564fe5f5e7d7
Van Rhee, F.
0928f5f5-f11e-4e3f-a3e4-8e27910398eb
Kaeda, J.
97eba745-9c30-4333-9235-00c915b12cf6
Cross, N. C.
f87650da-b908-4a34-b31b-d62c5f186fe4
Craddock, C.
10587977-6515-440b-92fb-0b5dd2190bfe
Kanfer, E.
d2fe82c8-6e91-4587-95f7-2a174ad95ce5
Apperley, J.
622c945c-74c1-4773-a80f-2bdafe8dfe14
Goldman, J. M.
2c27a1b3-c445-4593-a6b5-2e6e749fa1cb
Mughal, T. I., Yong, A., Szydlo, R. M., Dazzi, F., Olavarria, E., Van Rhee, F., Kaeda, J., Cross, N. C., Craddock, C., Kanfer, E., Apperley, J. and Goldman, J. M.
(2001)
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse.
British Journal of Haematology, 115 (3), .
(doi:10.1046/j.1365-2141.2001.03155.x).
Abstract
We identified 103 consecutive patients who, 5 years after allogeneic transplantation for chronic myeloid leukaemia (CML), were in molecular remission (MR). The 103 patients were divided into three groups on the basis of reverse transcription–polymerase chain reaction (RT–PCR) studies for BCR-ABL transcripts in the first 5 years post transplant: Group A comprised 63 patients who had been continuously PCR negative; Group B comprised 20 patients with one or more positive PCR result but only at a low level; and Group C comprised 20 patients who had fulfilled the criteria for molecular relapse, been treated with donor lymphocyte infusions (DLI) and had thereafter regained complete MR within the 5-year post-transplant period. The median follow-up for all 103 patients was 8·4 years from transplant (range 5–17·6 years). In group A only one patient relapsed at 9·2 years. In group B eight patients (40%) relapsed: six at molecular, one at cytogenetic and one haematological levels. The actuarial probabilities of survival at 10 years for patients in Groups A, B and C were 97·4%, 92·9% and 100% respectively; the probabilities of relapse were 3%, 54% and 0% respectively. We conclude that molecular studies during the first 5 years post transplant can help to predict long-term leukaemia-free survival and, possibly, cure of CML.
This record has no associated files available for download.
More information
Published date: 2001
Identifiers
Local EPrints ID: 24880
URI: http://eprints.soton.ac.uk/id/eprint/24880
PURE UUID: 5db23ca3-efda-425f-b46d-9fc95fdc7969
Catalogue record
Date deposited: 03 Apr 2006
Last modified: 16 Mar 2024 03:23
Export record
Altmetrics
Contributors
Author:
T. I. Mughal
Author:
A. Yong
Author:
R. M. Szydlo
Author:
F. Dazzi
Author:
E. Olavarria
Author:
F. Van Rhee
Author:
J. Kaeda
Author:
C. Craddock
Author:
E. Kanfer
Author:
J. Apperley
Author:
J. M. Goldman
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics